Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.00001 per share
Symbol
TSHA on Nasdaq
Shares outstanding
275,000,000
Price per share
$5.09
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
267,399,511
Total reported value
$1,470,534,653
% of total 13F portfolios
0%
Share change
+5,648,718
Value change
+$45,595,353
Number of holders
190
Price from insider filings
$5.09
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $90,456,313 +$7,574,932 27,662,481 +9.1% RA Capital Management, L.P. 30 Sep 2025
Manning Paul B 9.8% $59,394,578 25,601,111 Paul B Manning 30 May 2025
RTW INVESTMENTS, LP 8.3% -16% $120,312,664 -$9,129,432 23,407,133 -7.1% RTW Investments, LP 31 Dec 2025
BlackRock, Inc. 6.5% +26% $98,187,600 +$25,844,308 17,852,291 +36% BlackRock, Inc. 31 Dec 2025
MORGAN STANLEY 6.7% -21% $44,506,820 -$2,034,437 16,858,644 -4.4% Morgan Stanley 30 Jun 2025
Vestal Point Capital, LP 5% $70,675,000 13,750,000 Vestal Point Capital, LP 31 Dec 2025
FMR LLC 4.9% -22% $74,406,012 -$11,547,008 13,528,366 -13% FMR LLC 31 Dec 2025
GOLDMAN SACHS GROUP INC 5.1% $33,274,806 12,748,968 THE GOLDMAN SACHS GROUP, INC. 26 Jun 2025
Octagon Capital Advisors LP 3.3% -36% $29,650,725 -$4,520,775 9,067,500 -13% Octagon Capital Advisors LP 30 Sep 2025

As of 31 Dec 2025, 190 institutional investors reported holding 267,399,511 shares of Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA). This represents 97% of the company’s total 275,000,000 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) together control 84% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 8.6% 23,555,648 0% 1.3% $129,556,064
Avoro Capital Advisors LLC 7.9% 21,700,000 0% 1.2% $119,350,000
BlackRock, Inc. 6.8% 18,643,129 +14% 0% $102,537,212
MORGAN STANLEY 6.6% 18,078,518 -6.4% 0.01% $99,431,850
RTW INVESTMENTS, LP 6% 16,398,297 -33% 0.9% $90,190,634
Vestal Point Capital, LP 5% 13,750,000 +150% 2.8% $75,625,000
GOLDMAN SACHS GROUP INC 5% 13,692,739 +2.3% 0.01% $75,310,065
FMR LLC 4.9% 13,528,366 -7.3% 0% $74,406,012
VANGUARD GROUP INC 4.8% 13,267,805 +3.3% 0% $72,972,929
STATE STREET CORP 3.9% 10,790,084 +49% 0% $59,345,462
Siren, L.L.C. 3.7% 10,129,913 -8% 1.7% $55,714,522
Octagon Capital Advisors LP 3.2% 8,859,911 -2.3% 6.1% $48,729,511
Polar Capital Holdings Plc 2.9% 7,931,403 +50% 0.2% $43,622,717
BARCLAYS PLC 2% 5,539,001 +7.6% 0.01% $30,464,506
GEODE CAPITAL MANAGEMENT, LLC 2% 5,387,026 +4.1% 0% $29,633,569
D. E. Shaw & Co., Inc. 1.5% 4,013,635 +48% 0.02% $22,074,993
BAKER BROS. ADVISORS LP 1.5% 4,004,756 0% 0.13% $22,026,158
Point72 Asset Management, L.P. 1.4% 3,868,682 -47% 0.03% $21,277,751
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 1.4% 3,722,000 0.03% $20,471,000
Affinity Asset Advisors, LLC 1.2% 3,300,000 +10% 1.3% $18,150,000
MILLENNIUM MANAGEMENT LLC 1.2% 3,178,863 -21% 0.01% $17,483,746
DEERFIELD MANAGEMENT COMPANY, L.P. 0.99% 2,722,165 -49% 0.19% $14,971,908
ADAR1 Capital Management, LLC 0.91% 2,495,809 -12% 1% $13,726,950
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.69% 1,902,978 +3.1% 0% $10,466,379
CITADEL ADVISORS LLC 0.67% 1,854,855 +405% 0.01% $10,201,703

Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 267,399,511 $1,470,534,653 +$45,595,353 $5.50 190
2025 Q3 264,455,712 $864,768,038 +$29,349,082 $3.27 152
2025 Q2 257,684,976 $595,324,582 +$211,768,578 $2.31 147
2025 Q1 166,761,354 $231,855,383 -$5,171,826 $1.39 124
2024 Q4 167,381,791 $289,604,775 +$18,983,312 $1.73 126
2024 Q3 156,893,147 $315,365,141 -$17,620,277 $2.01 114
2024 Q2 158,086,076 $354,139,573 +$33,881,138 $2.24 102
2024 Q1 140,148,555 $402,080,424 +$33,453,660 $2.87 106
2023 Q4 130,129,882 $230,288,972 -$12,329,934 $1.77 85
2023 Q3 129,862,060 $410,364,849 +$376,246,041 $3.16 59
2023 Q2 13,698,356 $9,051,371 -$2,014,707 $0.66 37
2023 Q1 16,687,605 $13,286,354 -$3,025,814 $0.80 42
2022 Q4 19,375,255 $43,785,515 +$12,385,904 $2.26 51
2022 Q3 13,927,007 $27,020,000 -$1,811,564 $1.93 48
2022 Q2 14,700,530 $54,695,000 -$11,594,670 $3.72 55
2022 Q1 17,015,055 $110,894,239 -$16,224,000 $6.52 70
2021 Q4 18,503,286 $215,562,592 -$15,412,583 $11.65 64
2021 Q3 19,436,846 $361,910,267 +$4,396,852 $18.62 48
2021 Q2 18,320,557 $388,394,891 +$15,022,269 $21.20 48
2021 Q1 17,661,042 $358,518,075 -$11,587,017 $20.30 46
2020 Q4 17,998,551 $475,216,635 +$32,037,839 $26.54 51
2020 Q3 16,580,732 $366,712,000 +$366,712,000 $22.40 46